Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease — Stella

Home/Huntington Disease/

View on ClinicalTrials.gov

Recruiting

Back to Huntington Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of California, Irvine, Irvine, California

Key details

Phase

Early testing / Safety & dosing

Sponsor

Leslie Thompson

Collaborators

California Institute for Regenerative Medicine (CIRM), University of California, Irvine

Enrollment target

~21 participants

Started

April 2026

Primary completion

June 2028

Age range

18 Years – 65 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.